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Doppel (Dpl) is a membrane-bound glycoprotein mainly expressed in the testis of adult healthy people. It is generally absent in the
central nervous system, but its coding gene sequence is ectopically expressed in astrocytoma specimens and in derived cell lines. In
this paper, we investigated the expression and the biochemical features of Dpl in a panel of 49 astrocytoma specimens of diﬀerent
WHO malignancy grades. As a result, Dpl was expressed in the majority of the investigated specimens (86%), also including low
grade samples. Importantly, Dpl exhibited diﬀerent cellular localizations and altered glycan moieties composition, depending on
the tumor grade. Most low-grade astrocytomas (83%) showed a membrane-bound Dpl, like human healthy testis tissue, whereas
the majority of high-grade astrocytomas (75%) displayed a cytosolic Dpl. Deglycosylation studies with N-glycosidase F and/or
neuraminidase highlighted defective glycan moieties and an unexpected loss of sialic acid. To ﬁnd associations between glial tumor
progression and Dpl biochemical features, predictive bioinformatics approaches were produced. In particular, Decision tree and
Nomogram analysis showed well-deﬁned Dpl-based criteria that separately clustered low-and high-grade astrocytomas. Taken
together, these ﬁndings show that in astrocytomas, Dpl undergoes diﬀerent molecular processes that might constitute additional
helpful tools to characterize the glial tumor progression.
1.Introduction
Astrocytomas are human brain tumors that arise from
astrocytes, the most abundant type of glial cells of the central
nervous system, or, more likely, from resident cancer stem
cells. These tumors are divided into grades according to their
histological characteristics and following the classiﬁcation
guidelines given by the World Health Organization (WHO)
[1]. Unfortunately, the pathological classiﬁcation of astro-
cytomas is often problematic due to their extensive hetero-
geneity, thus suﬀering from the subjectivity of the anato-
mopathologists. Presently, low-grade astrocytomas include
pilocytic(WHOgradeI)anddiﬀuse(gradeII)astrocytomas,
whereas high-grade astrocytomas comprise anaplastic astro-
cytomas (grade III) and glioblastoma multiforme (GBM,
gradeIV).GBMsarethemostcommonandaggressiveforms
of these tumors in adults [2], and despite decades of research
on tumor biology, they continue to have a poor prognosis.
Median survival time of patients with GBM without treat-
ments is approximately 3 months, whereas it approaches to
one year following aggressive surgical and adjuvant therapy,
such as radio- and chemotherapy [3]. Therefore, there is a
pressing need for the elucidation of molecular mechanisms
involved in malignant cell transformation as well as for the
development of sensitive and speciﬁc biomarkers that enable
early and accurate diagnosis and prognostic prediction. In
this context, it is worth mentioning that genetic alterations
that drive glial cell transformation and malignant progres-
sion result in tumor-speciﬁc changes in protein expression
and/or posttranslational modiﬁcations [4–6].2 Journal of Biomedicine and Biotechnology
Recently, it has been reported that doppel (Dpl), a
prion protein family member mainly expressed in testis but
generally absent in central nervous system [7], is aberrantly
expressed in astrocytic tumors where it displays cellular
localization and molecular properties diﬀerent from those
of the corresponding testis protein [8–11]; Dpl in healthy
human testis is a glycoprotein of 126 amino acids, bound to
the cell surface through a glycosylphosphatidylinositol (GPI)
anchor [12, 13]. Although the cellular function of Dpl has
not still unravelled, its involvement in spermiogenesis and
in male fertility regulation has been suggested [14, 15]. The
aberrant expression of doppel protein was mainly investi-
gated in established astrocytoma cell lines, highlighting an
abnormal retention of the gene transcript within the nucleus
and an unusual cytoplasmic localization of the protein [10].
Inparticular,theproteindisplayedanincreasedglycosylation
proﬁle and a predominant accumulation within lysosomal
vesicles [10, 11]. Unfortunately, knowledge concerning the
molecular features of Dpl in tumor mostly originates from
studies performed on astrocytoma-derived cell lines that,
although recognized as a good model for pathogenesis,
they could display protein patterns that often do not
match the bioptic counterparts. Therefore, a biochemical
characterization of Dpl isolated from a collection of diﬀerent
grades of astrocytoma specimens has been undertaken. This
analysis was then coupled with a bioinformatics approach
to underline associations between Dpl biochemical and
expression features and glial tumor malignancy progression.
2.MaterialsandMethods
2.1. Human Biopsy Samples. Astrocytoma specimens were
provided by Dr. Benericetti (Azienda Ospedaliera di Parma,
Parma, Italy) and by Prof. Clelia Miracco (University of
Siena). These specimens were obtained by surgical resection
after informed consent of the patients and immediately
stored at −80
◦C. Sections of specimens were histologically
andmorphologicallyevaluatedbyindependentneuropathol-
ogists and classiﬁed according to the 2000 WHO guidelines.
Clinical data of the investigated astrocytoma patients (n =
49) are reported in (see Table1 in Supplementay Material
available online at doi:10.1155/2010/301067.) Human non-
neoplastic autoptic testis and brain tissues, respectively, as
Dpl-positive and Dpl-negative controls, were provided by
the “Dipartimento di Medicina Legale e Sanit` aP u b b l i c a ,
Universit` a di Pavia, Pavia, Italy”.
2.2. Dpl Extraction and Partial Puriﬁcation. Microsomal and
cytosolic fractions were prepared as previously described
[10].Therelativepurityofthefractionswascheckedassaying
the activity of both L-lactic dehydrogenase and glucose
6-phosphatase used as marker enzymes [16, 17]. Partial
puriﬁcation of Dpl was performed using a cation exchanger
precolumn(HiTrapSP,1mL,GE-Healthcare,Piscataway,NJ,
USA) arranged on the top of an anion exchanger column
(HiTrap Q, 5 mL, GE-Healthcare), equilibrated in 50mM
sodium phosphate pH 6.5, 1mM ethylenediamminete-
traacetic acid, and 1mM phenylmethylsulfonyl ﬂuoride.
Elution of bound proteins was performed separately, with a
0 to 1M NaCl linear gradient. Puriﬁed proteins were then
accurately quantiﬁed [18], and Dpl was detected by means
of 12% SDS-PAGE and by immunoblotting analysis using
a Dpl-speciﬁc antiserum (Dpl-Val), previously described in
[10, 11], and commercial IgG anti-Dpl goat (N-20) and
rabbit (FL-176) antisera (Santa-Cruz Biotechnologies).
2.3. Immunohistochemistry Dpl Detection. Immunohisto-
chemistry was performed on 3μm-thick sections, from
formalin-ﬁxed and paraﬃn-embedded glioblastoma frag-
ments, using the streptavidin-biotin peroxidase complex
method. Sections were dewaxed in Bio-Clear (Bio-Optica,
Milano, Italy) and rehydrated with graded ethanol until
distilled water. Endogenous peroxidase activity was blocked
by treating the slides with 3.0% hydrogen peroxidase in
distilled water for 10min, followed by three washes in
Tris/HCl buﬀer, pH 7.5. The antihuman Dpl-Val antibody
(1:200) was applied overnight at 4◦C. Dpl was detected
with the UltraVision LP Large Volume Detection System
HRP or AP Polymer (Ready-To-Use) (Bio-Optica) and
using diaminobenzidine (Dako, Milano, Italy) for 8min as
chromogen. Sections were then counterstained with Mayer’s
hematoxylin. Negative controls were performed by replacing
the primary antibody with a nonimmune rabbit serum.
2.4. Deglycosylation Assays. Chemical deglycosylation was
performed by triﬂuoromethanesulfonic acid (TFMS) as
described in [19]. Brieﬂy, 2mg (accurately determined as
before) of lyophilized protein was dissolved in 300μLo f
anisole/TFMS 1:2 and stirred at 25
◦C for 3h. The reaction
was neutralized by the gradual addition of 100μL pyridine,
and the sample was stored at −20
◦C for 1h. After addition
of trichloroacetic acid at the ﬁnal concentration of 25%, the
samples were centrifuged, twice washed with acetone and
subjected to 15% SDS-PAGE and immunoblotting analysis.
Enzymaticdeglycosylationwascarriedoutusingpeptide:
N-glycosidase F (PNGase F) or/and neuraminidase (New
England Biolabs, Ipswich, MA, USA) according to the
manufacturer. Brieﬂy, 100μgo fp r o t e i nw a sh e a td e n a t u -
rated for 10min in the presence of 0.5% SDS and 1%β-
mercaptoethanol. After an overnight incubation at 37
◦C
with 50mM sodium phosphate pH 7.5 and 1% NP-40 in
the presence of 1,000 U of PNGase F or/and 100 U of
neuraminidase,thereactionwasstoppedwithtrichloroacetic
acid, and the proteins were analyzed by 12% SDS-PAGE and
immunoblotting.
2.5. Two-Dimensional Polyacrylamide Gel Electrophoresis
(2D-PAGE). 2D-PAGE was performed using Immobiline
DryStrip pH 3–10 and IPG Buﬀer 3–10 (GE Healthcare)
as described in [20]. Proteins (60μg) were water dialyzed,
lyophilized, and resuspended in 200μLo f8 Mu r e a ,2 %
CHAPS, 2% IPG Buﬀer 3–10, and applied to the DryStrips
via the rehydration technique. Strips were focused on a
Multiphor II system (GE Healthcare) at 20
◦C with the
following program: 100V for 6h, 300V for 5h, 600V for
2h, 1000V for 1h, and 3000V for 3h. After isoelectricJournal of Biomedicine and Biotechnology 3
focusing, strips were incubated 30min in 50mM Tris/HCl,
pH 8.8, 6M Urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.1%
(w/v) bromophenol blue, layered onto a 12% SDS-PAGE,
and immunoblotted as before.
2.6. Statistical and Bioinformatics Analysis. To calculate the
signiﬁcance of microsomal-cytosolic distribution of Dpl
among WHO grades, an Anova one-ways test was
adopted, considering as signiﬁcant a P value less than
.05. The Decision tree and the Nomogram analysis
were performed using the Orange data mining software
(http://www.ailab.si/orange/). The molecular weight of Dpl
isoforms was calculated from molecular weights standards.
For densitometric evaluations, a relative scale from 1 to 10
values of Dpl quantity (in arbitrarily units) was assessed. For
Nomograms, interval conﬁdence of Probabilities (P)w a s
assessed at P = .95.
3. Results
3.1. Dpl Expression in Astrocytoma Specimens. To character-
ize Dpl expression in astrocytomas, 49 bioptic specimens,
graded according to the World Health Organization (WHO)
criteria [1], were mechanically lysed and fractionated
to obtain membrane-bound (microsomal) and/or soluble
(cytoplasmic) proteins. The relative purity of microsomal
and cytoplasmic fractions of all specimens was checked
assaying the activity of both L-lactic dehydrogenase and glu-
cose 6-phosphatase marker enzymes. L-lactic dehydrogenase
activity was found only in the cytosolic fractions, whereas
glucose 6-phosphatase activity was mostly present in the
microsomal ones (more than 95%), thus exhibiting only a
minimal percent in the cytosolic fraction. Taken together,
these data supported the good quality of both preparations
for each sample analyzed.
Along with their clinical features, clinical cases included
WHO grades I (2 samples), II (5), III (7), and IV (35) (Sup-
plementary Table 1). Human nonneoplastic controls from
autoptic testis and brain tissues (n = 2 each) were also frac-
tionated,andDplexpressionwasevaluated.Asexpected,Dpl
was undetectable in both cytosolic and microsomal fractions
ofbrain(datanotshown)aswellasintestiscytoplasmicfrac-
tions (Figure 1(a)). Conversely, Dpl was visualized as a single
band of approximately 31kDa in the microsomal fraction of
testis tissue (Figure 1(b)). In astrocytomas, Dpl was detected
in the majority of the analyzed specimens (42/49, 86%).
Diﬀerently, Dpl was undetectable in one WHO grade I and
in three WHO grade III and IV samples (data not shown).
As reported in Figure 1, Dpl was mostly expressed in the
soluble fraction of the specimens (38/42, 90%). Moreover,
the presence of the soluble Dpl alone was signiﬁcantly
associated with high- compared to low-grade samples
(Figure 1(c)). Ten specimens endowed with cytoplasmic
Dpl exhibited the protein also in the microsomal frac-
tion (Figure 1(b), samples 1,2,3,17,23,24,27,29,32,33),
whereas four specimens showed the protein exclusively
in the microsomal fraction (Figure 1(b), samples 39–42).
Interestingly, 83% of grade I and II tumors were char-
acterized by the presence of the membrane-bound Dpl,
whereas only 25% of high-grade samples exhibited this
molecular form (Figure 1(d)). Moreover, whereas cytoplas-
mic fractions, after immunoblotting, showed two or more
Dpl isoforms (Figure 1(a)), Dpl isolated from microsomal
fractions generally showed a single isoform of approximately
31kDa (Figure 1(b)). The authenticity as well as the repro-
ducibility of positive bands was conﬁrmed by subjecting to
immunoblotting experiments, both microsomal and soluble
fractions of three astrocytoma samples (one low-grade
and two high-grade), and using three diﬀerent primary
antibodies (i.e., Dpl-Val, N-20, and FL-176). A Dpl-positive
(testis) and a Dpl-negative (healthy brain) control were also
assayed (Supplementary Figure 1).
DiﬀerencesinDplsubcellularlocalizationwerealsohigh-
lighted by immunohistochemistry in diﬀerent glioblastoma
sections, showing a predominantly extensive cytoplasmic
localization, whereas a membrane immunostaining was less
frequently exhibited (Figures 2(a) and 2(b)). As expected
[9, 10, 12], in the cortex section of peritumoral area,
Dpl expression was faint compared to the neoplastic tissue
(Figure 4(c)).
3.2. Biochemical Characterization of Dpl in Astrocytomas.
Previously, it has been reported that Dpl protein in healthy
human testis is a glycoprotein, with two N-linked and one
O-linked oligosaccharide [14]. To compare glycan moieties
composition of Dpl in testis (microsomal fraction) and
in astrocytoma specimens (soluble fraction), chemical and
enzymatic deglycosylation studies were performed, after
a partial puriﬁcation by ion-exchange chromatography.
Because of the limited available amounts in low-grade
samples, four high-grade samples (i.e., 9,10,15,23) were
subjected to this biochemical characterization. After chem-
ical deglycosylation with TFMS treatment that removes total
sugars from glycoproteins and immunoblotting, in glial
tumor and in testis, Dpl migrated as a 15kDa protein
(Figure 3(a)), in accordance with the expected molecular
mass of the polypeptide chain [14, 21], this also proved
the integrity of Dpl in the specimens, following the above
mentioned treatments.
After PNGase F treatment that speciﬁcally digested the
N-linked glycan moieties, testis Dpl exhibited a 22kDa pro-
tein (Figure 3(b)), indicating the removal of approximately
9kDa of N-linked sugar chains. As a result, testis Dpl turned
out to have a nearly 7kDa O-bound oligosaccharide. More-
over, after a digestion with neuraminidase that removes the
terminal sialic acid residues, testis Dpl migrated as a 28kDa
protein, indicating that the total sialic acid mass removed
consisted of approximately 3kDa in mass. Lastly, a digestion
with neuraminidase in association with PNGase lowered
the band to about 20kDa, suggesting that the amount of
sialic acid lost exclusively by the O-ligated moiety of testis
Dpl amounted to nearly 2kDa (Figure 3(b)). Unfortunately,
digestion with O-glycosidase that removes O-linked glycan
moiety was unsuccessful (data not shown), preventing us
from corroborating data on oligosaccharide distribution.
Dpl cytoplasmic fractions in astrocytoma specimens
generally exhibited two or more bands with a molecular
mass ranging from 20 to 90kDa (Figure 1(a)). When4 Journal of Biomedicine and Biotechnology
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Figure 1: Identiﬁcation and cellular localization of Dpl in testis and astrocytoma samples. Immunoblotting analysis of cytoplasmic (a)
and microsomal (b) fractions. To limit the ﬁgure size, only positive samples have been reported. Dpl was detected with the anti-Dpl
rabbit antiserum (Dpl-Val) previously described in[10, 11], loading 20μg of puriﬁed proteins. Each astrocytoma sample is identiﬁed by a
progressive number followed by their WHO grade of malignancy (1/I, 2/II, etc.). (c) Distribution of Dpl in low- and high-grade astrocytoma
samples as a cytoplasmic fraction (black bars), microsomal fraction (white bars) and in both fractions (grey bars). (d) Distribution of
microsomal Dpl in low- and high-grade astrocytoma samples, regardless of the presence/absence of the cytosolic protein. Asterisks indicated
statistically signiﬁcant Anova One-way probabilities (P).Journal of Biomedicine and Biotechnology 5
(a) (b)
Cortex Glioblastoma
(c)
Figure 2: Dpl immunohistochemistry localization in glioblastoma and peritumoral cortex sections. Dpl was detected using Dpl-Val
antibody. Panels (a) and (b) represent sections of two diﬀerent glioblastomas, one of which showing a marked Dpl immunoreactivity in
the cytoplasm (Panel (a)), and the other at the plasma membrane (Panel (b)) (original magniﬁcation 200x). A low Dpl immunoreactivity is
exhibited by the peritumoral cortex (Panel (c), left), compared to the glioblastoma area (Panel (c), right) (original magniﬁcation 25x).
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Figure 3: Deglycosylation patterns of healthy human testis and glial tumor Dpl. Testis (microsomal fraction) and astrocytomas (soluble
fraction)glycoformsofDplwereanalyzedbychemicaldeglycosylationwithTFMS(a)andbyenzymaticdeglycosylationwithneuraminidase
and/or PNGase F (b), followed by immunoblotting using a Dpl-speciﬁc polyclonal antibody [10, 11]. U: untreated; T: TFMS treatment; N:
neuraminidase digestion; P: PNGase F digestion; C: neuraminidase plus PNGase F digestion.
cytoplasmic protein was digested with PNGase F, complex
electrophoretic patterns were obtained, suggesting a high
heterogeneity of the glycan moieties, even within the same
specimen (Figure 3(b)). On the other hand, the digestion
with neuraminidase left the molecular mass of all isoforms
unchanged, indicating that soluble Dpl was likely devoid
of sialic acid. The lack of an acidic component in the
soluble Dpl molecule was also evidenced through 2D-PAGE
Dpl protein analysis: all Dpl soluble isoforms exhibited
isoelectric point values (pI=5.9–6.5) higher than that of6 Journal of Biomedicine and Biotechnology
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Figure 4: Isoelectric point determination of Dpl protein in nonneoplastic human testis and in glioblastoma multiforme (GBM) samples.
2D-PAGE was performed using 60μg of puriﬁed protein samples on a linear immobilized pH gradient (i.e., pH 3–10), followed by a 12%
SDS-PAGE. Dpl was then detected by immunoblotting as reported above.
the Dpl isolated testis protein (pI = 5.3), as illustrated in
Figure 3.
3.3. Bioinformatics Analysis. Then, Dpl expression and bio-
chemicalfeaturesweretentativelycorrelatedwithglialtumor
progression using a bioinformatics-derived approach; Dpl
expressionpatternswerecataloguedaccordingtoDplrelative
densitometric expression (RQ, adopting a scale from 1 to 10
arbitrary units), to the cellular topology (i.e., Dpl expressed
in microsomal fractions, cytosolic fractions, or both), to the
apparent molecular mass of Dpl isoforms, to the 2000 WHO
tumor malignancy grading criteria, and ﬁnally, according
to the anatomical localization of the tumor specimens
(Supplementary Table 1). After a Decision tree analysis, Dpl-
positive tumor samples were roughly subdivided into two
main branches, according to the molecular mass of Dpl
isoforms (Figure 5): for Dpl masses lower than 47.5kDa,
low-grade astrocytoma samples (i.e., WHO grades I and II)
were clustered; in this group, a minority of WHO grade IV
samples (9/32, 28%) were also identiﬁed. Diﬀerently, the
majority of WHO IV specimens (23/32, 72%) clustered at
Dpl mass higher than 47.5kDa. Importantly, all anaplastic
astrocytoma classiﬁed samples (WHO III) were distributed
in this branch, according to: (i) a Dpl molecular weight
higher than 74kDa, (ii) a Dpl RQ minor or equal to 6.5,
and (iii) to a Dpl cytosolic localization of the protein. To
furtherconﬁrmthis partition, tumorspecimens werefurther
grouped in two main classes, low-grade (WHO I and II)
and high-grade astrocytoma (WHO grade III and IV) and
subjected to a Nomogram analysis to evaluate the perfor-
mance of the above-mentioned Dpl-related molecular and
cellularcriteriaindistinguishingtumor-gradingprogression.
This analysis, reported in Figure 6, highlighted that the
highest probabilities (P = .95) to sort the samples according
to the two main target classes (i.e., low-and high-grade
astrocytomas)wereobtainedincorrespondencetolowerDpl
mass and RQ and to a microsomal localization for low grade
samples: On the contrary, the highest probability to correctly
identify high-grade samples was associated with high Dpl
molecular weights and RQ and to a cytoplasmic protein
localization, as evidenced in the previous Decision tree anal-
ysis. As expected, the anatomical localization of the tumor
specimens, as well as their age and gender, did not inﬂuence
the estimation of the probabilities for the two classes.
4. Discussion
Previous studies performed on the aberrant expression of
doppel (PRND) gene in astrocytoma bioptic specimens and
in derived-astrocytoma cell lines showed that transcripts
levels were associated with glial tumor progression [8, 9].
To ascertain whether the expression of doppel (Dpl) proteinJournal of Biomedicine and Biotechnology 7
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Figure 5: Decision tree analysis according to Dpl characterization in astrocytoma specimens. The adopted Dpl-based criteria at the
decision nodes are reported (i.e. molecular mass of Dpl isoforms, MW; relative quantity of Dpl expression, RQ; Dpl topology, C=cytosol,
M=microsomal or CM=both). WHO grading and sample percentages are indicated.
might also be associated with the glial tumor grading
progression, we performed for the ﬁrst time a biochemical
characterization of Dpl in a collection of astrocytoma
specimens, deriving a predictive bioinformatics model to
ascertain the malignancy grade of these tumors.
At a molecular level, Dpl turned out to be expressed
in nearly all tumor specimens investigated (86%) also
including low-grade astrocytomas. This suggested that Dpl
expression might represent one of the primitive alter-
ations that accompanies the malignant transformation in
astrocytomas. According to our results, this tumor grad-
ing transition in astrocytomas was much more depicted
considering Dpl topologies within the specimens: Dpl
shifted from a microsomal-membrane-associated localiza-
tion in low-grade samples to a predominant cytoplasmic
distribution in anaplastic astrocytoma and in glioblastoma
multiforme samples. Similarly, this cytosolic localization of
Dpl was evidenced also in astrocytoma-derived cell lines
[10].
From a biochemical point of view, microsomal Dpl
in astrocytomas was similar to the corresponding testis
protein. Thus, Dpl, at the onset of the disease, is likely to
be anchored to the outer leaﬂet of the plasma membrane,
through its GPI moiety. Afterwards, as the tumor progresses,
Dpl could fail to anchor to the membrane and localize
within the cytoplasm. The reason for this behaviour is
presently puzzling, also in the light of our previous results
that excluded mutations in the GPI attachment site of the
protein [10]. On the other hand, chemical deglycosylation
performed on cytoplasmic Dpl led to a protein of 15kDa,
the same value displayed by the microsomal Dpl similarly
treated. Thus, the aberrant localization of Dpl should not be8 Journal of Biomedicine and Biotechnology
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Figure 6: Nomogram association analysis between Dpl features and astrocytomas. Astrocytoma specimens, grouped in low-(WHO I and
II) and high-grade (WHO III and IV), were then associated with Dpl molecular mass (MW), relative quantity (RQ), and topology (topo,
C:cytosol, M:microsomal, and CM:both) data. Continuous line-delineated sectors corresponded to target probabilities for low-or high
grading sorting of P = .95. Total points indicated the sum of the points for each variable.
ascribed to alterations of the polypeptide chain, but rather to
some unusual posttranslational modiﬁcations. Actually, the
presence of Dpl in the cytosol was mostly associated to an
increase of the protein molecular mass and to the number
of its isoforms. Therefore, we hypothesized that the soluble
Dpl was endowed with heterogeneous, more complex, and
larger glycan moieties, even within the same sample. As a
matter of fact, enzyme deglycosylation assays agreed with
this hypothesis. In some cases, PNGase showed to be able to
digest the astrocytoma soluble Dpl, although to a diﬀerent
extent (Figure 2(b), samples 9 and 10), whereas in others,
it left the protein unchanged (sample 23). Notably, even the
isoforms of the same specimen were found to be diﬀerently
digested (sample 9), suggesting that the tumor Dpl might
contain a defective glycan moiety, possibly due to an
impairment of the cell glycosylation machinery. In addition,
it is diﬃcult to ascertain whether the failure of PNGase to
digest Dpl was related to an actual lack of N-glycosylated
component or to a steric hindrance created by these larger
glycan moieties. Moreover, the presence of an uncommon
fucoseintheproximityoftheN-glycosylationsitescannotbe
excluded [4]. Certainly, the cytosolic Dpl was characterized
by unusual glycosylation processes. Unluckily, the present
datadonotallowtounraveltheactualdistributionofN-and
O-glycan components in Dpl isoforms and to decipher the
molecular moieties accountable for the high Dpl molecular
mass. By all means, all Dpl astrocytoma isoforms turned
out to be devoid of sialic acid, as previously documented
in astrocytoma-derived cell lines [10]. The alteration of
sialylation pattern is not a novelty in malignancy, although
generally the extent of sialylation results was increased rather
than lowered in tumors [22]. Thus, the loss of sialic acid inJournal of Biomedicine and Biotechnology 9
astrocytoma Dpl seems a peculiar biochemical feature that
might be further investigated.
Diﬀerent bioinformatics analyses were performed to bet-
ter elucidate if the above-mentioned Dpl protein signatures
mightbeassociatedwiththeglialtumorgradingprogression.
Initially, a supervised approach, based on the assumption
that the grouping (i.e., the histological tumor diagnoses
made by three independent neuropathologists) is correct,
was applied, excluding specimens with ambiguous grading
classiﬁcations. Finally, adopting the Orange Bioinformatics
platform, led to the deﬁnition of a Decision tree that
straightened into diﬀerent branches low-versus-high-grade
astrocytomas, based mostly on the molecular masses of
Dpl isoforms. Of note, three decision nodes (i.e., molecular
weight >74kDa, RQ < 6.5 and a cytoplasmic localization of
Dpl isoforms) subgrouped anaplastic astrocytomas within
the group of glioblastoma multiforme specimens. Na¨ ıve
Bayesan-based Nomograms further highlighted that low-
and high-grade astrocytomas had complementary distribu-
tions in terms of microsomal and cytoplasmic localization
of Dpl isoforms, the former also characterized by lower
expression and low molecular weight of Dpl isoforms.
In conclusion, a biochemical characterization and a
bioinformatics analysis of Dpl expression in a panel of astro-
cytomaspecimensallowedtoparallelmolecularsignaturesto
the glial tumor malignancy grading progression. Despite Dpl
potential usefulness in diagnosis, the function of this protein
in glial tumor progression remains elusive and worthy of
further studies.
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